Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 294 institutions reported holding it in 13F filings for Q2 2026, worth $4.00B in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Denali Therapeutics Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 213 | 2 | 190 | −21 |
| Shares | 85.3M | 54.2K | 86.8M | +1.55M (+1.8%) |
| Value | $3.80B | $2.42M | $2.79B | −$1.01B (−26.6%) |
2 institutions that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Denali Therapeutics Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Squarepoint Ops LLC | 34,435 | $1.11M | 0.01% |
| Duality Advisers, LP | 34,200 | $1.10M | 0.12% |
| Walleye Capital LLC | 28,296 | $910.0K | 0.03% |
| Eaton Vance Management | 23,057 | $742.0K | 0.00% |
| Twinbeech Capital LP | 18,046 | $581.0K | 0.03% |
| PDT Partners, LLC | 17,850 | $574.0K | 0.05% |
| Amalgamated Financial Corp. | 14,893 | $479.0K | 0.00% |
| E Fund Management Co., Ltd. | 8,827 | $284.0K | 0.01% |
| Bridgewater Associates, LP | 6,867 | $221.0K | 0.00% |
| Ergoteles LLC | 6,693 | $215.0K | 0.01% |
| Aquatic Capital Management LLC | 1,100 | $35.0K | 0.05% |
| Exchange Traded Concepts, LLC | 492 | $16.0K | 0.00% |
| Umb Bank N A | 444 | $14.0K | 0.00% |
| Signaturefd, LLC | 53 | $2.00K | 0.00% |
| Massmutual Trust Co FSB | 26 | $1.00K | 0.00% |
| TCWP LLC | 34 | $1.00K | 0.00% |
| Central Trust Co | 4 | $0 | 0.00% |
| Institutional & Family Asset Management, LLC | 6 | $0 | 0.00% |
| Global Retirement Partners, LLC | 3 | $0 | 0.00% |
Sold out (40)
Institutions that held Denali Therapeutics Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
Not filed for Q1 2022 yet (2)
Institutions that held Denali Therapeutics Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Tygh Capital Management, Inc. | 54,226 | $2.42M |
| Bell Investment Advisors, Inc | 11 | $0 |